BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 31464648)

  • 21. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
    Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
    Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
    Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
    Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
    Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
    Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.
    Xia JT; Wang H; Liang LJ; Peng BG; Wu ZF; Chen LZ; Xue L; Li Z; Li W
    Pancreas; 2012 May; 41(4):629-35. PubMed ID: 22249132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A robust 6-mRNA signature for prognosis prediction of pancreatic ductal adenocarcinoma.
    Zhou C; Zhao Y; Yin Y; Hu Z; Atyah M; Chen W; Meng Z; Mao H; Zhou Q; Tang W; Wang P; Li Z; Weng J; Bruns C; Popp M; Popp F; Dong Q; Ren N
    Int J Biol Sci; 2019; 15(11):2282-2295. PubMed ID: 31595147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
    Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
    World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Calomme A; Demetter P; Delpero JR; Svrcek M; Cros J; Bardier-Dupas A; Puleo F; Monges G; Hammel P; Louvet C; Paye F; Bachelier P; Le Treut YP; Vaillant JC; Sauvanet A; André T; Salmon I; Devière J; Emile JF; Van Laethem JL
    Clin Cancer Res; 2015 Mar; 21(5):1215-24. PubMed ID: 25552484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population.
    Maehira H; Miyake T; Iida H; Tokuda A; Mori H; Yasukawa D; Mukaisho KI; Shimizu T; Tani M
    Ann Surg Oncol; 2019 Dec; 26(13):4791-4804. PubMed ID: 31583548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma.
    Gong R; Wang J; Xing Y; Wang J; Chen X; Lei K; Yu Q; Zhao C; Li S; Zhang Y; Wang H; Ren H
    Cancer Lett; 2024 May; 590():216838. PubMed ID: 38561039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
    Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
    Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
    JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.
    Wang L; Gu F; Liu CY; Wang RJ; Li J; Xu JY
    Tumour Biol; 2013 Apr; 34(2):853-8. PubMed ID: 23242609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).
    Lianyuan T; Dianrong X; Chunhui Y; Zhaolai M; Bin J
    Cancer Biol Ther; 2018 Apr; 19(4):296-305. PubMed ID: 29313457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
    Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
    Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
    Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
    Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis.
    Huang YK; Liu H; Wang XZ; Zhu S
    Asian Pac J Cancer Prev; 2014; 15(22):9921-6. PubMed ID: 25520129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.